Small cap₹101 cr₹0.5 cr traded a dayThin: a ₹2 lakh order is 3.6% of a normal day
Close on 11 September 2026
50.68
+1.38%
52-week range100% of the way up
16.9650.68
Market cap
101 cr
P/E (TTM)
66.2×
EPS (TTM)
0.77
Revenue YoY
+455.7%
Q1 FY27
Profit YoY
+409.8%
Net margin
4.9%
-0.4pt vs a year ago
Growth trend
+257.5pt
vs last quarter’s YoY
1 month
+8.9%
Below 52w high
0.0%
RSI (14)
66
Daily swing
4.5%
average true range
Volume
1.2×
vs 20-day average
Traded
₹1 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Top of the universe
+88.1%
One-year return
Top of the universe
+165.2%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
3 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
+455.7%
Below the 52-week high
distance from the highest close of the year
0.0%
How it has performed
price return over each window, beside the median NSE stock over the same days
The read
written from the numbers on this page
More of the measured facts point up than down7 supporting, 1 against, 0 worth knowing
Supporting
trading 88% above its 200-day average
sitting at 100% of its 52-week range, with little overhead supply from trapped buyers
up 165% over twelve months
matches gapped up and held it, which has beaten the market by +2.83 points over 20 sessions across 11,705 past signals
8 of the scans it matches have a positive measured record
4 independent kinds of evidence agree today, which is uncommon
revenue grew 456% year on year in the quarter ending 30 June 2026
Against
net margin has narrowed from 6.3% to 4.9% across four quarters
Worth knowing
nothing the data supports either way
The market itself is rangebound tonight. Each scan's record is measured separately for this regime; the figure beside each chip above is the one that applies, not the all-weather number.
What would change these counts: the close crossing its 200-day average, which is 27 tonight and moves every session; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working6
Revenue +455.7% year on year, Rs 4 cr to Rs 25 cr.
+455.7%Rs 4 crRs 25 cr
Net profit +409.8% year on year, Rs 0 cr to Rs 1 cr.
+409.8%Rs 0 crRs 1 cr
Trading 88.1% above its 200-day simple average, which is the line most investors use to separate a bull phase from a bear one.
+88.1%
Within 0.0% of its 52-week high.
0.0%
Up 165.2% over the past year.
+165.2%
4 different kinds of evidence point at it tonight, not 4 versions of the same one.
4 families
Needs watching2
Profit grew slower than revenue, +409.8% against +455.7%.
+409.8%+455.7%
Only ₹0.5 crore changes hands on a median day. A large order moves this price by itself.
₹0.5 cr
Every figure here is computed — from the company’s own filings, or from its own closing prices. The wording is generated directly from the figures.
What the scans say today
12 of 57 matched on 11 Sep
VEERHEALTH matches 12 of the 57 scans today, across 4 different kinds of evidence (not counting 2 that match most of the market tonight). Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses. It is in the published portfolio of 1 of the 19 methods on the arena tonight.
Tonight VEERHEALTH is in the published portfolio of 1 of the 19 methods the arena runs. Each is a rule set from a named book or paper, applied mechanically to every company we scan and published before the outcome is known. The record beside each is what that method’s earlier positions did against the market while held — the method’s history, not a forecast for this name.
“Holds for” is the method’s stated window in sessions; a name leaves its book when the rules drop it or the window runs out. Every method, its rules and its full ledger are on the arena.
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 456% against the same quarter a year earlier
profit rose 410% year on year
net margin widened from -2.1% to 4.9%
revenue rose in 3 of the last 4 quarters
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · standalone
25
1
1
0.61
4.9%
Q4 FY26
31 Mar · standalone
17
0
0
—
-2.1%
Q3 FY26
31 Dec · standalone
7
0
0
0.20
5.6%
Q2 FY26
30 Sep · standalone
4
0
0
0.13
6.3%
Q1 FY26
30 Jun · standalone
4
0
0
0.12
5.4%
Q4 FY25
31 Mar · standalone
6
0
0
—
-1.8%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Valuation against its own history
142 sessions since 16 February 2026
49×
median 63×
160×
now 66×
VEERHEALTH trades at 66× trailing earnings, close to its median of 63× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
How it is priced against the universe
tonight’s multiples, ranked against every company we scan
Measure
Tonight
Where it ranks
Price to earnings
trailing four quarters of profit
66.2×
cheaper than 15% of scanned companies
Price to sales
trailing four quarters of revenue
1.92×
cheaper than 58% of scanned companies
Earnings yield
1.5%
profit as a share of the market value — the P/E upside down
P/E to growth
0.16
the multiple divided by the year-on-year profit growth rate
Value composite
63
average percentile across the three multiples; 0 is the cheapest company scanned, 100 the dearest
Quality checklist
five of Piotroski’s nine tests, the ones Indian filings support
2 of 5
✓ profitable over four quarters✗ cash conversion above 100%✗ borrowings under half of equity✗ margin up on a year ago✓ revenue up on a year ago
A low multiple is a statement about expectations, not about quality: the market usually expects less from a cheap company, and is often right. These are rankings, not fair values.
AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423) · Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · Management filings were typically +0.06pt vs the market over the next 5 sessions (n=2,634)
Who bought size here
bulk and block deals disclosed to NSE and BSE, internal transfers removed
Everything disclosed in VEERHEALTH over the last 40 sessions came on one day, 27 July 2026: 2 trades, 236,000 shares bought and 106,987 sold by the names below, so a net +129,013 (+0.65% of the equity) came from holders too small to have to report. The largest seller was SHILPABEN ALPESHBHAI SHAH, the largest buyer BHAVIK RAJAN KAPADIA. The stock has moved +20.2% since.
Session by session, last 40 sessions · up and green when more shares were bought than sold, down and red when more were sold, a flat mark where nothing was disclosed
20 Jul11 Sep
Session
Side
Counterparty
Shares
Price
Value
27 Jul
Bought
BHAVIK RAJAN KAPADIA
individual · BSE
236,000
42.20
₹1.0cr
27 Jul
Sold
SHILPABEN ALPESHBHAI SHAH
individual · BSE
106,987
42.20
₹0.5cr
How to read this. A bulk deal is a single trade of more than half a percent of the company’s shares; a block deal is a large trade negotiated off the order book. Both must be disclosed the same day, with the counterparty’s name. When the same name appears on both sides of the same stock on the same day it is an internal transfer and is removed before anything here is counted. Who the counterparty is comes from its name and is a guess. Across every disclosed buy on file, the stock was +0.09% against the market 20 sessions later on average, ahead of it 41% of the time, over 1,370 deals. After a disclosed sell: -1.34% against the market, ahead 41% of the time, 1,439 deals. A disclosure says what someone did, not why, and nothing here says what happens next. Full tape on the Who bought size page.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+13.2%
Versus 200-day average+88.1%
Below 52-week high0.0%
Above 52-week low+198.8%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)65.6
Higher closes in last 54 of 5
Six-month return+154.42%
Risk and liquidity
What a position costs to hold and to exit. Delivery is the share of the day’s volume taken into demat rather than squared off; trade size says whether the day’s tickets were large or small.
Typical daily swing (ATR)4.46%
What ₹1 lakh here moves on a normal dayabout ₹4,462
Volume versus 20-day1.2x
Median daily turnover₹0.5 cr
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.